Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Clarus Revise Target

4/27/2022 Clarus Securities Reiterated Rating Buy C$26.50  rate and reply


HLS Therapeutics Reiterated by Clarus Securities C$33.00 Buy  rate and reply


Still looking for a double. GLTA Canaccord Genuity’s Tania Armstrong-Whitworth lowered her HLS Therapeutics Inc. target by 25 cents to $30.50 with a “buy” rating. The average is $30.58.  rate and reply


08:20 AM EDT, 03/17/2022 (MT Newswires) -- HLS Therapeutics Inc. (HLS.TO), a pharmaceutical company focusing on central nervous system and cardiovascular markets, on Thursday reported, in US$, that more

More Good Looking Targets

A very illiquid stock and a very quiet BB but now might be the time to start paying attention. GLTA HLS THERAPEUTICS (TSE:HLS) ANALYST RATINGS HISTORY 12/16/2021 Raymond James more

Canaccord 2022 Top Picks

Reopening and public access to bring the pulse back Investment recommendation HLS is a specialty pharma company focused on bringing innovative central nervous system (CNS) more

Promotional Agreement with Pfizer for Vascepa® in Canada

Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on more